This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on July 29, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

MaxCyte ExPERT GTx Electroporation Device and Installation/Operational Qualification (IQ/OQ)

Closed

26-008363Federal

Submission Closed08/07/2026, 06:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Federal

Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Solicitation # 75A50126R00001_RFP_NPIVS_27

BARDA is seeking contractors to support the Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. The selected providers will be responsible for furnishing all necessary personnel, materials, and facilities to produce vaccines, antigens, and adjuvants for pandemic preparedness and public health emergencies. This includes generating and submitting critical analytical, clinical, and manufacturing data to the FDA to ensure rapid regulatory decisions and manufacturing readiness. To be eligible for this award, offerors must have experience producing vaccines against influenza and strains with pandemic potential. Mandatory qualifications include either holding a U.S. influenza vaccine license or demonstrating the development of an influenza vaccine through the submission of a Biologics License Application for seasonal or pandemic vaccines. This solicitation is managed by the Department of Health and Human Services with a response deadline of October 30, 2026.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Industry Day: DARPA Documentation & Decision Support Sprint (D2)

Solicitation # DARPA-SN-26-118

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

DARPA Surgical Competition (DSC) Industry Day

Solicitation # DARPA-SN-26-125

The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is hosting an Industry Day for the DARPA Surgical Competition (DSC) on September 22, 2026, from 9:00 AM to 12:30 PM ET. This hybrid event, held in Arlington, Virginia, and virtually, aims to introduce a competition focused on developing a minimum viable product for scalable, autonomous robotic trauma surgery systems. The competition is designed to establish the state of the art for open robotic trauma surgery and identify technologies for autonomous surgical assistance. Performance will be evaluated through three primary lanes: Component Gates, which assess system safety and autonomy across medical knowledge, physical capability, and rapid learning; Surgical Collaboration, which tests the platform's ability to work alongside a human surgeon; and Surgical Independence, which evaluates the system's ability to plan and execute end-to-end trauma procedures without assistance. While this special notice is not a formal request for proposals, interested parties are invited to participate by registering and optionally submitting materials by September 18, 2026. These materials include a single-slide landscape PDF for a three-minute lightning talk and a teaming profile detailing technical competencies and collaboration goals. All submissions must contain only unclassified, non-proprietary information. Technical and administrative inquiries are managed by Program Manager Jeremy Pamplin via the SurgicalCompetition@darpa.mil email address.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Human Hindbrain Organoid Functional Assay Services.

Solicitation # RFQ_CDR-2026-135968

The U.S. Food and Drug Administration's Center for Drug Evaluation and Research is seeking a firm-fixed-price purchase order for human induced pluripotent stem cell-derived hindbrain organoid functional assay services. The contract involves the provision of human hindbrain organoids and associated culture materials, with twelve scheduled deliveries to the FDA White Oak Campus in Silver Spring, Maryland. The first delivery will consist of 96 organoids, followed by eleven subsequent deliveries of 48 organoids each. The contractor will perform functional characterization at its own laboratory using three-dimensional multi-electrode array technology to evaluate electrophysiological responses to FDA-identified drug and reversal-agent combinations. Key deliverables include the raw and analyzed data, analysis files, and comprehensive study reports. The anticipated period of performance is 18 months from the date of award. This is a commercial service acquisition under FAR Part 12, intended as a sole-source award to OrganoTherapeutics SARL based on market research identifying them as the only source capable of meeting the full requirement. Award will be based on best value, with technical capability and past performance weighted more heavily than price. All invoicing must be processed electronically through the U.S. Department of Treasury's Invoice Processing Platform.

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Hypoxia Chamber Services

Solicitation # 80JSC026Q0008

NASA Johnson Space Center is soliciting combined synopsis and request for quotations under solicitation 80JSC026Q0008 for Hypoxia Chamber Services to support the Artemis Program. The objective is to investigate the physiological, cognitive, and clinical effects of mild hypobaric hypoxia through two 7-day test protocols involving continuous habitation for six subjects at air equivalent altitudes of 7,000 and 9,500 feet. The scope of work encompasses the provision of infrastructure, personnel, training, materials, and operational support. The contract is structured as a firm fixed price agreement with a base period from September 15, 2026, to September 30, 2027, and multiple option periods extending through March 1, 2030. The acquisition is open to all responsible sources under NAICS code 541714, with a size standard of 1,000 employees. Evaluation is based on a trade-off process where technical acceptability and past performance are significantly more important than price. Proposals must be submitted via email to the designated points of contact by October 1, 2026, following an extension granted in Amendment 0004. Key requirements include the submission of FAR 52.212-3 representations and certifications and adherence to specific submission criteria regarding team qualifications and risk assessment. The contract also incorporates strict guidelines regarding the protection of sensitive information and restrictions on funding activities with China.

NASA Johnson Space Center

POSTED

DEADLINE

Hypobaric Chamber Pilot Studies

Solicitation # 80JSC026Q0006

NASA Johnson Space Center is soliciting quotes under solicitation 80JSC026Q0006 for pilot hypobaric chamber testing facilities to support decompression sickness research. The primary objective is to validate non-NASA resources for safe prebreathe procedures and extravehicular activity to support Artemis mission planning. The base requirement consists of three test days, with a minimum of two subjects per day, collecting and recording data according to research protocols. The contract also includes six optional work items, including additional test days, inflight-like treatment preparation, elevated metabolic rate testing, pharmaceutical-enhanced prebreathe, and body temperature studies. The base period of performance runs from September 1, 2026, to September 30, 2027, with various option periods extending through March or September 2029. This is a small business set-aside acquisition under NAICS code 541714. Awards will be made based on a trade-off analysis where technical acceptability and past performance are significantly more important than price. Technical evaluation focuses on facility capabilities, medical support, team expertise, and the proposed schedule for subject throughput. Offerors must provide a price quotation using the provided pricing sheet, and quotes must remain valid for at least 90 days. Following several amendments, the final deadline for the submission of offers is October 1, 2026, at 1:00 p.m. Central Time. All submissions must be sent electronically to the designated points of contact.

NASA Johnson Space Center

POSTED

DEADLINE

Undiagnosed Diseases Network (UDN) Diagnostic Research Innovation CenterThe National Institutes of Health, through the NINDS, is forecasting the establishment of a Diagnostic Research Innovation Center to support the next phase of the Undiagnosed Diseases Network. This center will operate as part of a broader ecosystem including the Clinical and Data Coordinating Center, Networks of Diagnostic Excellence, and the NIH Undiagnosed Diseases Program. The primary objective of the center is to advance innovative diagnostic tools and strategies for both genomic and non-genomic conditions, which includes the systematic re-evaluation of unsolved cases from previous network phases. The center will focus on generating and testing diagnostic hypotheses by utilizing advanced sequencing, multi-omics, and gene function studies in animal and human in vitro models. By collaborating with various network stakeholders, the center aims to identify novel disease-associated genes, genomic variants, and new syndromes. This initiative seeks an integrated center featuring investigators with a history of scientific synergy and collaboration. While this is currently a forecast to allow potential applicants time to plan and establish partnerships, formal applications are not yet being solicited.

National Institutes Of Health

POSTED

DEADLINE

study entitled “Malaria and vector borne disease surveillance in the Colombia/Venezuela border”

Solicitation # ERP_1301373256

The Naval Medical Research Unit South in Lima, Peru, is seeking a provider to conduct a study focused on malaria and vector borne disease surveillance along the Colombia and Venezuela border. While the government has identified the Administrators of Tulane Educational Fund as the only vendor currently capable of supporting the entire requirement, they are issuing this notice to identify other capable sources before proceeding with a sole source award under FAR 13.106-1(b)(i). Interested parties must submit a capability statement including technical, management, and cost data to Genaro Vasquez via email by 12:00 PM local time on September 18, 2026. Submissions must be in Microsoft Word or PDF format, not exceed five pages, and use the subject line ERP_1301373256. The government will use these submissions to determine whether to pursue a competitive procurement or move forward with the intended sole source contract.

Naval Medical Research Center

POSTED

DEADLINE

Cryo-Electron Microscopy (Cryo-EM) Services

Solicitation # 75N98026Q01177

The National Institutes of Health Olao, under the Department of Health and Human Services, is seeking providers for Cryo-Electron Microscopy (Cryo-EM) Services under solicitation number 75N98026Q01177. This combined contract opportunity is categorized under NAICS code 541714 and is managed by the office located in Bethesda, Maryland. Interested parties must submit their responses by the deadline of September 16, 2026, at 6:00 PM. The primary point of contact for this procurement is Roxane S. Burkett.

National Institutes Of Health Olao

POSTED

DEADLINE

TIDAL: Target-Induced Droplet Assembly of Ligands

Solicitation # S-197478

Developed by Los Alamos National Laboratory, TIDAL (Target-Induced Droplet Assembly of Ligands) is a programmable protein-only material that utilizes nanobodies fused with encapsulation peptides to create dynamic, liquid-like droplets through phase separation. This technology allows for the precise concentration of binders upon encountering a target ligand, enabling a versatile platform for resin-free protein purification, high-sensitivity diagnostics, and the creation of slow-release drug depots. It can also function intracellularly to sequester and neutralize harmful proteins associated with viral infections or cancer. The technology is currently at TRL 3 with a patent pending and is available for exclusive or non-exclusive licensing through the Department of Energy contractor, Triad. Key market applications span biopharmaceutical manufacturing, therapeutics, and biotechnology. Interested parties can contact Caleb Ledgerwood or Lindsay Augustyn via the provided licensing email to explore commercial partnerships for this innovation.

Triad - DOE Contractor

POSTED

DEADLINE

Master Protocol Development & Adaptive Design

POSTED

DEADLINE

Phase I/II Clinical Trial Management & Execution

W6QK Acc-Apg

POSTED

8 days ago

DEADLINE

in 5 days

General Info

Agency

Department Of Health And Human Services → National Institutes Of Health OlaoView Agency

Contract Value

$126,250

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Awardee

MAXCYTE, INC.View Profile

Award Issued Date

08/19/2026, 12:00:00 AM UTC

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed

PostedJul 29

Presolicitation

Response DeadlineAug 7

Deadline has passed

Submission Closed

08/07/2026, 06:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao

Contacts1 person available

OfficeBETHESDA, MD, 20892, USA

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health Olao

View Agency Profile

Office AddressBETHESDA, MD, 20892, USA

Contacts

Shasheshe Goolsby

contact@example.gov

+1 (555) 000-0000

Full Description

MaxCyte ExPERT GTx Electroporation Device and Installation/Operational Qualification (IQ/OQ)

Product Service Code (PSC): 6640 – Laboratory Equipment and Supplies

NAICS Code: 541714 – Research and Development in Biotechnology (except Nanobiotechnology)

Size Standard: 1,000 Employees

Place of Performance:

National Institutes of Health

Clinical Center

Bethesda, MD 20892

POTS: 26-008363

Description

This notice is issued for informational purposes only and does not constitute a request for quotations. A solicitation will not be issued and quotations will not be requested.

The following items are required for this procurement:

Units/Part Number/Description

1/E-GTX-A/Expert GTx Flow Electroporation Platform for cGMP and Clinical Applications, Generation 3 with accessories

1/IQOQ/IQOQ Services and Installation

1/Estimated Freight

The National Institutes of Health (NIH), Clinical Center, Office of Purchasing and Contracts, on behalf of the Center for Cellular Engineering, intends to award a firm-fixed-price contract on a sole source basis to MaxCyte, Inc., Rockville, MD 20850, for the purchase of a MaxCyte ExPERT GTx Electroporation Device and associated Installation Qualification/Operational Qualification (IQ/OQ) services.

Background

The Center for Cellular Engineering (CCE) manufactures cell-based therapies for patients who have either exhausted all standard treatment options or have no available standard therapies.

CCE manufacturing operations are regulated under Current Good Manufacturing Practices (cGMP) as mandated by the U.S. Food and Drug Administration (FDA) under:

21 CFR Part 210

21 CFR Part 211

21 CFR Part 600

21 CFR Part 1271

The electroporation device is used to introduce genetic material (DNA, RNA) and proteins into cells during the development and manufacturing of cell-based therapies.

The current electroporation system in use at CCE is the MaxCyte Gen2 GT model, which will no longer be supported by the manufacturer beginning in mid-2026. To maintain continuity of ongoing clinical manufacturing protocols and ensure continued compliance with cGMP manufacturing standards, the Center must transition to the MaxCyte ExPERT GTx system.

The ExPERT GTx device will replace the current system and includes installation, operational qualification (IQ/OQ), and preventative maintenance services required to maintain validated manufacturing equipment in a regulated cGMP environment.

Technical Capabilities of the MaxCyte ExPERT GTx

The MaxCyte ExPERT GTx platform provides several capabilities required for clinical cell therapy manufacturing, including:

FDA Master File supported platform, simplifying IND and CMC regulatory submissions

GMP-compliant closed electroporation system suitable for clinical manufacturing

High transfection efficiency in primary cells, including T cells, NK cells, and hematopoietic stem cells

High cell viability and preservation of cellular function following electroporation

Clinical-scale processing capability, supporting billions of cells in a single run

Scalable platform supporting research, clinical, and commercial manufacturing stages

Non-viral delivery capability, reducing complexity and cost associated with viral vectors

Compatibility with multiple cargo types, including DNA, mRNA, CRISPR RNPs, proteins, and other molecules

Highly reproducible and standardized manufacturing processes

Established clinical track record in cell and gene therapy manufacturing

The MaxCyte ExPERT GTx is widely recognized as a clinical manufacturing standard for electroporation-based gene modification in cell therapy production.

Sole Source Justification

MaxCyte, Inc. is the original equipment manufacturer and sole provider of the proprietary ExPERT GTx electroporation platform, associated disposable processing assemblies, and required IQ/OQ validation services.

No other vendor is known to provide an electroporation platform that:

Supports clinical-scale electroporation for cell therapy manufacturing

Operates within a fully closed, cGMP-compliant system

Maintains compatibility with existing validated protocols used within the NIH CCE manufacturing environment

Provides manufacturer-certified IQ/OQ qualification services required for regulated GMP manufacturing

As a result, MaxCyte, Inc. is the only source reasonably available to provide the required equipment and associated qualification services.

Authority

This acquisition is being conducted in accordance with:

FAR 13.106-1(b)(1) – Soliciting from a Single Source

Under this authority, contracting officers may solicit from a single source when the contracting officer determines that only one source is reasonably available.

Acquisitions conducted under FAR Part 13 – Simplified Acquisition Procedures are exempt from the competition requirements of FAR Part 6.

Responses

This notice is not a request for quotations. However, interested parties may submit capability statements demonstrating their ability to provide equipment and services equivalent to the MaxCyte ExPERT GTx electroporation platform.

Capability statements must clearly demonstrate the ability to provide:

Clinical-scale electroporation technology

cGMP-compliant cell therapy manufacturing systems

FDA-compatible regulatory documentation support

Manufacturer-validated IQ/OQ services

The Government will evaluate capability statements received in response to this notice. The determination not to compete this requirement is solely within the discretion of the Government.

Submission Instructions

Responses referencing POTS: 26-008363 must be submitted electronically to:

Shasheshe Goolsby

Team Leader

Hospital and Laboratory Support Division

Office of Acquisitions and Logistics Management

National Institutes of Health

Email: shasheshe.goolsby@nih.gov